Osteoarthritis

 This technology has been patented since 2022, extended in Europe, USA, China, Japan and Canada. 

Description

Osteoarthritis is a debilitating and painful condition with a significant long-term economic impact. There is currently no treatment capable of reversing or stopping the progression of osteoarthritis, and existing treatments are primarily aimed at controlling pain.

We propose a new treatment for osteoarthritis based on the repositioning of a small molecule initially used in the treatment of Parkinson's disease. This molecule targets a protein expressed in the chondrocytes and synoviocytes of the joint, which is overexpressed in patients with osteoarthritis. The injection of this pharmacological inhibitor directly in the joints both slows the progression of the disease and reduces pain in osteoarthritis patients and markers of inflammation in vivo. We plan to eventually offer a new formulation for intra-articular injection of this small molecule, thereby limiting its potential systemic effects. This will ultimately enable us to offer a new therapeutic solution for osteoarthritis patients. 

We are looking for a licensee or a co-development deal.